Triple antiviral therapy with telaprevir after liver transplantation: a case series

[Successful eradication of genotype 4 HCV with telaprevir-based triple antiviral therapy].

similar rigidity but a different biology (chronic pancreati-tis vs pancreatic cancer). 4,7 At present it can be useful in cases with negative FNAB or as a guide for directing FNAB into zones that have a greater probability of malignancy (hard) and avoid necrotic tissue (soft). It cannot yet replace EUS-guided FNAB. Further studies are required that evaluate and determine the specific role of EU...

A case of successful treatment with telaprevir-based triple therapy for hepatitis C infection after treatment failure with vaniprevir-based triple therapy.

Recently direct-acting antiviral agents, such as hepatitis C virus (HCV) non-structural 3/4A (NS3/4A) protease inhibitors (PI), have been introduced, and triple therapy regimens that include PI with conventional pegylated interferon α and ribavirin have significantly improved the sustained virological response (SVR) rate, up to 80% for both treatment-naïve and treatment-experienced patients wit...

effects of antiviral therapy on the recurrence of hepatocellular carcinoma after curative resection or liver transplantation

context hepatocellular carcinoma (hcc) is a fatal disease. chronic hepatitis b virus (hbv) and/or hepatitis c virus (hcv) infection is the major cause of hcc. high viral replication rate and related hepatic/systematic inflammation are the major risk factors in hcc recurrence after hepatectomy or liver transplantation. evidence acquisition some of the carcinogenesis-related hbv mutations are als...

Telaprevir-based triple therapy for hepatitis C null responders among living donor liver transplant recipients.

Telaprevir (TVR), a direct -acting protease inhibitor, was recently reported to improve treatment efficacy when used in combination with peg-interferon (PEG-IFN) and ribavirin (RBV) as triple therapy for HCV in non-transplant patients. The aim of the present study was to investigate the feasibility of TVR-based triple therapy among Japanese living donor liver transplant (LDLT) recipients who ha...

Antiviral therapy of recurrent hepatitis C in liver transplantation.